AbbVie Inc.
ABBV Healthcare Drug Manufacturers General
AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS grew 290.4%, free cash flow fell 36.2% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.
Follow ABBV
AbbVie Inc. (ABBV) Net income
AbbVie Inc.'s net income for fiscal 2025 was $4.2B, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $6.3B. Over the past ten years it has ranged from $4.2B (fiscal 2025) to $11.8B (fiscal 2022) — the current reading is the lowest in ten years. Net income has fallen for 3 consecutive fiscal years. AbbVie Inc. ranks 9th of 21 Drug Manufacturers General companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $4.2B | (1.24%) |
| FY2024 | $4.3B | (12.05%) |
| FY2023 | $4.9B | (58.86%) |
| FY2022 | $11.8B | 2.56% |
| FY2021 | $11.5B | 149.87% |
| FY2020 | $4.6B | (41.36%) |
| FY2019 | $7.9B | 38.60% |
| FY2018 | $5.7B | 7.12% |
| FY2017 | $5.3B | (10.82%) |
| FY2016 | $6.0B | 15.73% |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | $3.6B | 418.79% |
| Mar 2026 | $697.0M | (61.60%) |
| Dec 2025 | $1.8B | 865.43% |
| Sep 2025 | $188.0M | (80.02%) |
| 42 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| LLY Eli Lilly and Company compare | $26.7B |
| JNJ Johnson & Johnson compare | $21.0B |
| NVS Novartis AG compare | $12.7B |
| AZN AstraZeneca PLC compare | $12.6B |
| AMGN Amgen Inc. compare | $8.7B |
| ABBV AbbVie Inc. | $6.3B |
| PFE Pfizer Inc. compare | $4.4B |
| MRK Merck & Co., Inc. compare | $3.2B |
| GILD Gilead Sciences, Inc. compare | −$3.2B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on ABBV
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement